BMS Presents Clinical and RWE Data of Mavacamten for Obstructive Hypertrophic Cardiomyopathy at ACC 2021

 BMS Presents Clinical and RWE Data of Mavacamten for Obstructive Hypertrophic Cardiomyopathy at ACC 2021

Shots:

  • The company presented new analysis data from the P-III EXPLORER-HCM trial assessing mavacamten in patients with oHCM that tested the impact of the therapy on patients’ health status i.e symptoms, function, and QoL
  • The company unveils the interim results from MAVA-LTE, 5yrs. extension study of the EXPLORER-HCM. The study demonstrated improvement in LVOT gradients, diastolic function, NT-proBNP, and symptoms and was well tolerated
  • The company also presented real-world data analysis measuring the clinical & economic burden of oHCM in the US. Mavacamten is an oral, allosteric modulator of cardiac myosin for patients with oHCM

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: StraitTimes

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post